单克隆抗体在过去几十年成功地融入了肺癌的治疗领域。近年来，随着技术的进步，双特异性抗体（bsAbs）在恶性癌症治疗方面也显示出了强大的疗效，包括肺癌。这些抗体靶向两种独立的表位或抗原，并且已经在肺癌的转化与临床研究中得到了广泛的探索。在此，我们概述了bsAbs的作用机制、相关临床数据、正在进行的临床试验以及在临床研究中各种类型的bsAbs的有效新化合物，特别是在肺癌领域。我们还提出了bsAbs的未来发展方向，可能为患有肺癌的患者带来治疗新纪元。版权所有©2023中国医师协会，由沃尔特斯·克鲁威尔公司根据CC-BY-NC-ND许可协议生产。

Monoclonal antibodies have been successfully incorporated into the current therapeutical landscape of lung cancer in the last decades. Recently, with technological advances, bispecific antibodies (bsAbs) have also shown robust efficacy in the treatment of malignant cancers, including lung cancer. These antibodies target two independent epitopes or antigens and have been extensively explored in translational and clinical studies in lung cancer. Here, we outline the mechanisms of action of bsAbs, related clinical data, ongoing clinical trials, and potent novel compounds of various types of bsAbs in clinical studies, especially in lung cancer. We also propose future directions for the clinical development of bsAbs, which might bring a new era of treatment for patients with lung cancer.Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.